Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (192)	12/8/1999 6:17:00 PM
From: Curtis E. Bemis	Read Replies (1) \| Respond to of 395

Yup, an opportunity for the have-nots and I agree. I was just thinking about a small, bright bunch of folks trying to "make it happen". There is this magic thing for small companies and that is a sustained market cap of 100M$. That would attract more institutional investors--that is when RGEN trades at a bit over 4.5 and that is where they were yesterday. I think the next set of Secretin trials will be quite different.

To: JMarcus who wrote (192)	12/10/1999 11:09:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 395

> What you call tragic, I call a buying opportunity < Marc, at $3 or a little under, you've had company. Remember that high volume a couple months ago? Look at all the activity by Rosenwald / Paramount / Aries during June through September. Here's data through Sept 30 -- biz.yahoo.com Also, Paramount had a hand in the $9M private placement last May -- at $2.50 a share. "Participants in the financing included funds managed by Wellington Management Company, LLP. Paramount Capital acted as a financial advisor to the Company. " Surely, if I knew about the North Carolina slam report last summer, they did too -- and were buying ahead of its wide dissemination. --------------- Does anyone have more recent data? Were they still buying when RGEN was in the high 3s and 4s? -------------- Another question. On these threads, I've noticed occasional deprecatory references to Rubinwald. I hate riddles. Would someone please fill me in? Cheryl PS Despite lots of negatively slanted publicity throughout the recent popular press -- especially in the NY Times -- the stock has held at $3, and the volume has settled down. Things could have been a lot worse, short term.